Comparative Efficacy and Safety of Vancomycin, Linezolid, Tedizolid, and Daptomycin in Treating Patients with Suspected or Proven Complicated Skin and Soft Tissue Infections: An Updated Network Meta-Analysis

Feng, Jingjuan; Xiang, Feng; Cheng, Jian; Gou, Yeli; Li, Jun

doi:10.1007/s40121-021-00456-0

Cited by 8 publications

(10 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results contrast with our research results. In 2021, Feng et al performed a NMA to evaluate the effectiveness and safety of vancomycin, linezolid, daptomycin, and tedizolid in the skin and soft tissue infection; the results of this study were consistent with ours (Feng, et al 2021). The study by Feng et al assessed drug-related severe and adverse reactions without distinguishing hepatotoxicity, nephrotoxicity, and thrombocytopenia.…”

Section: Discussionsupporting

confidence: 85%

“…The study showed that MRSA prevalence ranged from 0-73% at 19 sites in the Asia-Paci c region from 2000 to 2016 (Lim, et al 2019). Recently, the rate of MRSA infection has been increasing sharply (Feng, et al 2021), posing a challenge to the health system in terms of di cult therapy, extended length of hospital stay, expanded health costs, and high mortality (Feng, et al 2021;Jones, et al 2020). Pneumonia has gained immense attention in the medical eld because of its high mortality and complex therapeutic management (Jones, et al 2020;Torres, et al 2021).…”

Section: Introductionmentioning

confidence: 99%

“…Orally or intravenously administered antibiotics are essential therapeutic agents against MRSA infections (Feng, et al 2021). According to the 2021 guideline of the UK and the 2011 guideline of the Infections Disease Society of America (IDSA), vancomycin, linezolid, teicoplanin, daptomycin, and tigecycline are recommended as the therapeutic drugs for MRSA infections (Brown, et al 2021;Liu, et al 2011).…”

Section: Introductionmentioning

confidence: 99%

“…However, with the development and emergence of new antibiotics, it is no longer clear which offers higher therapeutic e cacy. Much recent research has been conducted on the effectiveness and safety of different antibiotics in therapy for MRSA-caused infectious diseases (Feng, et al 2021;Jiang, et al 2013;Kato, et al 2021;Maraolo, et al 2021;Yue, et al 2016). The head-to-head meta-analysis compared the e cacy and safety of any two antibiotics only, such as vancomycin and linezolid, vancomycin and daptomycin, etc., in only one of the various MRSA-caused diseases (Feng, et al 2021;Jiang, et al 2013;Kato, et al 2021;Maraolo, et al 2021;Yue, et al 2016).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Comparative effectiveness and safety of five antibiotics in treating MRSA infections: A network meta-analysis

Zhang

Hong

et al. 2023

Preprint

View full text Add to dashboard Cite

A considerable number of researches compared the effectiveness and safety different antibiotics for a disease caused by MRSA. However, comprehensive evaluated antibiotic therapeutic different diseases caused by MRSA is lacking. The network meta-analysis (NMA) comprehensively compared the effectiveness and safety of linezolid, teicoplanin, daptomycin, and tigecycline with vancomycin in treating methicillin-resistant Staphylococcus aureus (MRSA)-caused diseases. PubMed, Embase, Web of Science, Cochrane Library, CNKI, and Wan-fang databases were searched for studies until Sep 28, 2021. All eligible randomized controlled trials of five antibiotics were included in the NMA, and their effectiveness and safety were compared in various MRSA-attributed diseases. The dichotomous variables adopted for the odds ratio (OR) and the surface under the cumulative ranking (SUCRA) to evaluate the incidence rate. The study was performed using Rev Man 5.4 and STATA 16.0 software. SUCRA analysis revealed the superiority of linezolid to other antibiotics in total effectiveness rate (98.9%), microbial killing rate (99.6%), and total nephrotoxicity (17.8%). Regarding safety, the total adverse reaction rate of vancomycin was inferior to teicoplanin (OR 0.49, 95% CI 0.30–0.80). Vancomycin total hepatotoxicity was inferior to linezolid (OR 0.36, 95% CI 0.18–0.73) and tigecycline (OR 0.15, 95% CI 0.03–0.66), and it was also inferior to linezolid (OR 0.33, 95% CI 0.24–0.47) and teicoplanin (OR 0.35, 95% CI 0.18–0.69) in total nephrotoxicity. Linezolid had a higher risk of thrombocytopenia than teicoplanin (OR 4.24, 95% CI 1.26–14.24) and vancomycin (OR 2.14, 95% CI 1.17–3.90). Moreover, linezolid exhibited higher effectiveness in pneumonia compared to vancomycin (OR 2.06, 95% CI 1.58–2.69) and teicoplanin (OR 1.67, 95% CI 1.06–2.62). For skin and soft-tissue infections, linezolid showed superior effectiveness to vancomycin (OR 1.62, 95% CI 1.20–2.18). Regarding the microbial killing rate, vancomycin was inferior to linezolid in pneumonia (OR 0.38, 95% CI 0.29–0.49), skin soft-tissue infection (OR 0.41, 95% CI 0.21–0.79), and other infections (OR 0.40, 95% CI 0.20–0.83). And teicoplanin was inferior to linezolid in treating pneumonia (OR 0.51, 95% CI 0.33–0.81) and other infections (OR 0.39, 95% CI 0.18–0.86). The present research suggest that linezolid may be a better option for treating MRSA-caused diseases. However, caution is warranted owing to linezolid-associated thrombocytopenia.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparative effectiveness and safety of five antibiotics in treating MRSA infections: A network meta-analysis

Zhang

Hong

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Its interaction with selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors was found to be minimal [22]. A recent meta-analysis assessing the clinical and microbiological successes of tedizolid vs. linezolid showed no significant difference between the two drugs [35 ▪ ]. In addition, tedizolid was tolerated and caused less optic and peripheral neuropathy, gastrointestinal side effects and myelosuppression/thrombocytopenia than linezolid [36,37].…”

Section: Oral Antibiotic Therapy For the Treatment Of Methicillin-res...mentioning

confidence: 99%

New drugs for methicillin-resistant Staphylococcus aureus skin and soft tissue infections

Hindy

Haddad

Kanj

2021

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of reviewStaphylococcus aureus is a pathogen incriminated in skin and soft tissue infections (SSTIs), with methicillinresistant S. aureus (MRSA) becoming the predominant cause and representing a significant burden to the healthcare system. The last updated Infectious Diseases Society of America (IDSA) guidelines concerning MRSA infections and SSTIs management were published in 2011 and 2014, respectively. The UK updated guidelines for MRSA infection treatment were published in 2021. Older treatment options may be associated with toxicity and require frequent dosing. There is a paucity of recent reviews on the armamentarium of new agents for MRSA SSTIs treatment. Recent findingsSince 2005, several new antibiotics received a fast-track approval by the Food and Drug Administration (FDA) for SSTI treatment. These drugs include delafloxacin, omadacycline, tedizolid, ceftaroline, dalbavancin, oritavancin and telavancin. In this manuscript, we will review the data that led to these new drugs approval and discuss their advantages and disadvantages in MRSA SSTIs management. SummaryMRSA is a major cause of SSTIs. Several novel therapies covering MRSA were FDA-approved for SSTIs. However, the current IDSA guidelines for MRSA infection and SSTIs as well as the recently published UK guidelines on MRSA treatment only consider these drugs as alternative choices or do not mention them at all. Keywordsacute bacterial skin and skin structure infections, methicillin-resistant Staphylococcus aureus, skin and soft tissue infections admissions for SSTIs was increasing by 30% from 2000 to 2004, a more recent study showed a decrease of 15.8% in MRSA-related hospitalizations between 2010 and 2014 [7,8].Historically, community-acquired MRSA (CA-MRSA) was genetically different from hospitalacquired-MRSA (HA-MRSA) and could be clinically differentiated because it was essentially causing limited to uncomplicated SSTIs [9]. However, the

show abstract

Antibacterial Agents

Lewis,

Bush

2023

ClinMicroNow

View full text Add to dashboard Cite

Antimicrobial chemotherapy has played a vital role in the treatment of human infectious diseases since the discovery of penicillin in the 1920s. This chapter provides an overview of the antibacterial agents currently marketed in the United States, with major emphasis on their mechanisms of action, spectra of activity, important pharmacologic parameters, and toxicities. The major antibacterial action of penicillins is derived from their ability to inhibit multiple bacterial enzymes, namely, penicillin‐binding proteins (PBPs), that catalyze the last steps of peptidoglycan synthesis. The penicillins have antibacterial activity against most Gram‐positive and many Gram‐negative and anaerobic organisms. Like the penicillins, cephalosporins act by binding to PBPs of susceptible organisms, thereby interfering with the synthesis of peptidoglycan of the bacterial cell wall. Clavulanic acid is a naturally occurring weak antimicrobial agent found initially in cultures of Streptomyces clavuligerus . Streptomycin, neomycin, kanamycin, tobramycin, and gentamicin are naturally occurring aminoglycosides.

show abstract

Comparative Efficacy and Safety of Vancomycin, Linezolid, Tedizolid, and Daptomycin in Treating Patients with Suspected or Proven Complicated Skin and Soft Tissue Infections: An Updated Network Meta-Analysis

Cited by 8 publications

References 43 publications

Comparative effectiveness and safety of five antibiotics in treating MRSA infections: A network meta-analysis

Comparative effectiveness and safety of five antibiotics in treating MRSA infections: A network meta-analysis

New drugs for methicillin-resistant Staphylococcus aureus skin and soft tissue infections

Antibacterial Agents

Contact Info

Product

Resources

About